George P. Kim, MD: Expected Response with Liposomal Irinotecan
What level of response would you anticipate with the liposomal irinotecan regimen for this patient, based on data published in The Lancet earlier this year?
Metastatic Pancreatic Cancer: Case 2
Henry R was diagnosed with adenocarcinoma in the body of the pancreas when he was 64 years old, following rapid weight loss, abdominal pains, and the development of venous thrombosis.
- At diagnosis, measurable distant lymph node, liver, and lung metastases were observed
- His CA19-9 level was 2760 U/ml and his concentration of albumin was 28 g/L. His ECOG performance status was 1.
Upfront treatment was administered with nab-paclitaxel and gemcitabine, which lasted for 4months:
- At the time of progression, pain levels had increased interfering with daily activity and raising the ECOG performance status to a 2.
- At this point, second-line therapy was initiated with liposomal irinotecan, fluorouracil, and folinic acid.
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
